US/UK/Canada

Share

Pick a time period -
Tags ( Active)

BioStock: Patents and study in focus for Promore Pharma

When Promore Pharma looks back on 2022, it can look back on an eventful year with several important milestones achieved. 2023 does not promise to be any less hectic, in November the company announced that the results from the PHSU05 study with ensereptide for scarring on skin are expected to be available as early as April 2023. BioStock talked to CEO Jonas Ekblom about the past year and what awaits Promore Pharma.Read the full article about Promore Pharma at biostock.se: https://www.biostock.se/en/2023/03/patents-and-study-in-focus-for-promore-pharma/ This is a press release from

BioStock: Promore Pharma’s CEO on hopes for 2023

For Solna-based Promore Pharma, 2022 was characterised by steady advancement in the development of its drug candidate ensereptide. During the year, the company carried out a significant part of a phase II study with the candidate, which is being developed to inhibit scarring on the skin. At the same time, preparations for phase III studies are ongoing for the second candidate, ropocamptide. BioStock contacted CEO Jonas Ekblom to find out more about the company’s goals for 2023.Read the article at biostock.se: https://www.biostock.se/en/2023/01/promore-pharmas-ceo-on-hopes-for-2023/

BioStock: Promore Pharma’s leg ulcer treatment to reduce patient suffering

Promore Pharma's candidate ropocamptide is being developed for treatment of venous leg ulcers. This is a patient group that today largely lacks pharmaceutical treatment alternatives and Promore aims to reduce patient suffering as well as reduce the burden wound care places on the carer. For a clearer picture of the problem that Promore Pharma wants to solve, BioStock looks at how venous leg ulcers impact the lives of sufferers.Read the full article about Promore Pharma on www.biostock.se/en/ https://www.biostock.se/en/2022/09/promore-pharma-leg-ulcer-treatment-to-reduce-patient-suffering

BioStock: Promore Pharma advancing according to plan

The reporting season is in full swing, and biopharmaceutical company Promore Pharma has now joined the list of companies that have reported on the second quarter. CEO Jonas Ekblom emphasises that the first months of the year have been characterised by intensive work that has resulted in the company advancing its two candidates according to plan. BioStock took the opportunity to ask Ekblom three quick questions about the report.Read the article at biostock.se: https://www.biostock.se/en/2022/09/promore-pharma-advancing-according-to-plan/ This is a press release from BioStock -

BioStock: Promore Pharma strengthens IP-protection

On Wednesday, Solna-based Promore Pharma could kick off the autumn news flow with good patent news. The company has been granted a patent in Europe for the candidate ropocamptide, which is being developed for the treatment of venous leg ulcers. BioStock contacted CEO Jonas Ekblom for a brief comment on the importance of the approval and the company’s strategy for IP protection.Read the article at biostock.se: https://www.biostock.se/en/2022/08/promore-pharma-strengthens-ip-protection/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

BioStock: Last clinic visit completed in Promore Pharma’s ensereptide study

The most important activity for Promore Pharma in 2022 has been the phase IIa study with drug candidate ensereptide. The company announced earlier this week that the study participants have now completed the last clinic visit. The next step is to analyse the data, with the goal of presenting results sometime during the winter. BioStock conducted a brief interview with CSO Margit Mahlapuu.Read the full article at biostock.se: https://www.biostock.se/en/2022/06/last-clinic-visit-completed-in-promore-pharmas-ensereptide-study/ This is a press release from BioStock - Connecting Innovation

BioStock: Promore Pharma’s Q1 characterised by study progress

The reporting season is in full swing and Promore Pharma has now joined the companies that have reported on the first quarter of 2022. Published last week, the company’s report focuses primarily on the ongoing phase II study with lead candidate ensereptide. The first part of the year has been characterised by progress of the study, something that CEO Jonas Ekblom told BioStock more about.Read the full article at biostock.se: https://www.biostock.se/en/2022/05/promore-pharmas-q1-characterised-by-study-progress/ This is a press release from BioStock - Connecting Innovation & Capital.

BioStock: Promore Pharma aims to accelerate healing of venous leg ulcers

Peptide company Promore Pharma is undeniably in an exciting phase with two drug candidates in the field of wound treatment currently in late clinical development, ensereptide and ropocamptide. BioStock has previously taken a closer look at ensereptide, which is now undergoing a phase IIa study, and today we are placing the spotlight on ropocamptide, which is being prepared for a coming phase III study. We took the opportunity to ask CEO Jonas Ekblom a few questions to find out more.Read the whole interview with Promore Pharma's CEO Jonas Ekblom at biostock.se :

BioStock: Promore Pharma’s phase II study running according to plan

Solna-based pharmaceutical company Promore Pharma focuses on therapeutic peptides in wound care and scarring, two areas where there currently is a lack of pharmaceutical products. The lead project ensereptide is indicated for prevention of scarring, and the company is currently conducting a phase IIa study with the candidate. BioStock has taken a closer look at the ongoing study and its importance to the company.Read the full article at biostock.se:https://www.biostock.se/en/2022/04/promore-pharmas-phase-ii-study-running-according-to-plan/This is a press release from BioStock -

BioStock: Promore Pharma initiates patient recruitment

Last Wednesday, Solna-based Promore Pharma released its year-end report, and, on the same day, the company was able to communicate news regarding its phase II study with the candidate ensereptide. In accordance with the company’s timetable, the first patient has now been recruited for the study on scarring. BioStock contacted CEO Jonas Ekblom to find out more.Read the full interview with Jonas Ekblom at biostock.se: https://www.biostock.se/en/2022/02/promore-pharma-initiates-patient-recruitment/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

BioStock: Promore Pharma prepares phase II study

With its drug candidates, Promore Pharma targets two comprehensive patient groups whose access to pharmaceutical products is limited – wound care and scarring. The main project ensereptide is being developed to inhibit scarring, with the aim of initiating a phase IIa study in early 2022. The company's second candidate, ropocamptide, for the stimulation of healing of chronic leg ulcers, is currently undergoing product development for an upcoming phase III study. BioStock talked to Promore Pharma's CEO Jonas Ekblom to learn more.Read the full interview with Promore Pharma's CEO Jonas Ekblom

Promore Pharma Appoints Erik Magnusson as Chief Financial Officer

STOCKHOLM, 28 May 2020 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announce the appointment of Erik Magnusson as Chief Financial Officer for the company. Erik has extensive professional experience from the financial markets and the life science sector. He joins from Coop Online, where he has had the role Financial Manager/Business Controller since 2016.Erik Magnusson assumes the position in August 2020 and thereby replaces the company’s current CFO Jenni Björnulfson, who in April announced that she is leaving the company for a role in another

Report from the Annual General Meeting of Promore Pharma AB held on 26 May 2020

STOCKHOLM, 26 May, 2020 –Promore Pharma AB held its AGM on Tuesday, 26 May 2020. The main resolutions passed at the meeting were as follows.More detailed information about the contents of the resolutions may be obtained from the complete notice of the AGM and the complete proposals. The notice and complete proposals are available on the Company’s website, www.promorepharma.com. Adoption of balance sheets and profit and loss accounts It was resolved at the meeting to adopt the profit and loss account and balance sheet, as well as the consolidated profit and loss account and

Promore Pharma AB (publ) Interim report January – March 2020

· Net sales amounted to MSEK 0.0 (0.5) MSEK · The operating loss for the period was 7.3 (-5.5) MSEK · Net loss was 7.0 MSEK (-5.5) MSEK, corresponding to a loss per share of SEK 0.19 (-0.27) · Cash flow from operating activities amounted to -15.0 (-4.4) MSEK     · Cash and cash equivalents amounted to 45.9 (26.6) MSEK Significant events during the period January - March · The targeted number of 120 patients completing treatment in the HEAL LL-37 Phase IIb clinical trial with ropocamptide was reached Significant events after the reporting period · The company CFO

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2020

STOCKHOLM, 25 May 2020 – Promore Pharma AB (publ) publishes its interim report for the first quarter 2020 at 13.00 CET on 26 May 2020.The next day, 27 May, the company will host a webcast telephone conference at 10.00 CET, with President and CEO Jonas Ekblom and CFO Jenni Björnulfson, where an update for the quarter and the COVID-19 pandemic’s potential effects will be given. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet or telephone. To join the web conference, please use the following link: https:

Promore Pharma’s Annual Report 2019 Published

STOCKHOLM, 5 May, 2020 – The 2019 Annual report of Promore Pharma AB (publ) is now available on the company website.The annual report is available in PDF format on the company website at: https://www.promorepharma.com/en/section/investors/financial-reports/ Printed copies can be ordered from Promore Pharma AB, Fogdevreten 2, SE-171 65 Solna, or by e-mail: info@promorepharma.com For additional information, please contact Jonas Ekblom, VD Tel: [+46] 736 777 540 E-mail: jonas.ekblom@promorepharma.com Jenni Björnulfson, CFO Tel: [+46] 708 55 38 05 E-mail: jenni.

Notice of Annual General Meeting in Promore Pharma AB (publ)

The Annual General Meeting of Promore Pharma AB (publ) will be held on Tuesday, 26 May 2020 at 2 pm, in the premises of Advokaterna Liman & Partners, Grev Turegatan 38, Stockholm. Registration begins at 1:30 pm.right to attend and notification of the company Anyone wishing to attend the meeting must (i)      be entered as a shareholder in the share register kept by Euroclear Sweden AB as of 19 May 2020, and (ii)     give notice to the company of its intention to attend no later than 19 May 2020. Notification of attendance may be given in writing to the company by e-mail to info@

Promore Pharma´s CFO leaves the company in 2020

STOCKHOLM, 2 April 2020 -- Promore Pharma’s CFO Jenni Björnulfson has announced that she has decided to leave her role in the company for a position in another company.“The Board of Directors and I would like to thank Jenni for her commitment and efforts during the years she has worked for Promore Pharma. It's sad that Jenni leaves, but I wish her good luck in her new endeavors," says Jonas Ekblom, President and CEO of Promore Pharma. “We are well equipped to immediately start a recruitment process to secure a replacement for Jenni”, he continues. Jenni Björnulfson will remain in her

Promore Pharma reached the targeted number of patients completing treatment in the HEAL LL-37 Phase IIb clinical trial

STOCKHOLM, 24 March 2020 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announce that last patient has been dosed in the treatment phase of the company’s Phase IIb-study (HEAL) with LL-37, a new candidate drug for treatment of venous leg ulcers. The company reached its target of treating 120 patients with LL-37 for three months. The company assesses that results from the study can be presented in the fourth quarter 2020 in accordance with earlier communications.The aim with Promore Pharma’s phase IIb study with LL-37, HEAL (A Study in Patients

Promore Pharma AB (publ) Year-end report 2019

October to December 2019 · Net sales amounted to 1.5 (1.4) MSEK. · The operating loss for the period was 9.4 (-6.5) MSEK · Net loss was 9.4 (-7.2) MSEK, corresponding to a loss per share of SEK 0.38 (-0.35) · Cash flow from operating activities amounted to -0.3 (-8.7) MSEK · Cash and cash equivalents amounted to 60.5 (30.9) MSEK January to December 2019 · Net sales amounted to 3.9 (2.4) MSEK. · The operating loss for the period was 29.1 MSEK (-32.7) MSEK · Net loss was 28.9 (-32.5) MSEK, corresponding to a loss per share of SEK 1.16 (-1.61) · Cash flow from

Invitation to Presentation of Promore Pharma’s Year-end report for 2019

STOCKHOLM, 13 February 2020 – Promore Pharma AB (publ) publishes its Year-end report for 2019 at 16.00 CET on 18 February 2020.The next day, 19 February, the company will host a webcast telephone conference at 09.00 CET, with President and CEO Jonas Ekblom and CFO Jenni Björnulfson. After the presentation there will be a Q&A session. The presentation will be held in English. The conference can be accessed via computer, tablet or telephone. To join the web conference, please use the following link: https://global.gotomeeting.com/join/490242685 To join the telephone conference, please

Promore Pharma has finalized recruitment of patients in HEAL LL-37 early

STOCKHOLM, 10 December 2019 -- Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, today announce that all patients in the company’s Phase IIb-study (HEAL) with LL-37 for treatment of venous leg ulcers have been recruited. Results from the study are expected to be available in the fourth quarter 2020.The aim with Promore Pharma’s phase IIb study with LL-37, HEAL (A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37) is that 120 patients with venous leg ulcers (VLU) in Sweden and Poland should

Promore Pharma’s rights issue completed

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, AUSTRALIA, HONG KONG, NEW ZEALAND, SWITZERLAND OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE CONTRAVENING TO ANY APPLICABLE RULES.Promore Pharma AB (publ) (”Promore Pharma” or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders has been completed (the “Rights Issue”). The Rights Issue was subscribed to 80 percent, providing Promore Pharma with gross proceeds of

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe